Researcher's fears of ‘weaponized' data reignite focus on puberty-blocking drugs for transgender youth

The benefits of puberty-blocking drugs for transgender children have gained attention amidst claims that a major federally funded study's data was delayed due to fears of political misuse. Advocates for gender-affirming care argue that such claims exaggerate standard research caution. A significant study indicated that puberty blockers didn't improve the mental health of 95 children observed over two years. However, some experts suggest that these drugs might prevent mental health decline by alleviating body dysphoria. The therapy is seen as safe and reversible, with a proven track record in treating precocious puberty. Nevertheless, a controversial review in the UK questioned its rationale and effectiveness for mental health benefits, leading to reduced usage there. This comes amid growing restrictions in certain regions against gender-affirming care for minors. Despite legal hurdles, recent studies report high satisfaction with puberty blockers and hormone therapy among young people. There is concern that political climates might lead researchers to self-censor, potentially affecting crucial scientific discourse.